Most data reassure regarding TNF inhibitors and cancerThe Oncology ReportAccording to the ACR guidelines, any biologic agent can be used in a patient with solid malignancy or nonmelanoma skin cancer that was treated more than 5 years ago, while rituxim…
|
Nice recommends Roche’s MabThera
CSL Recruitment New draft guidance from the National Institute for Health and Care Excellence (Nice) has recommended the Roche drug MabThera (rituximab) as a treatment for adults with a rare type of vasculitis. The drug is licensed for bringing on remission in people … |
ProHealth |
If we can’t cure it, we’ll pretend it doesn’t exist
ProHealth Or consider the B-cell abnormalities and the spectacular response to Rituximab in ME/CFS that has been documented by Norwegian researchers. So we can see that the theories of auto-immune and ongoing viral infection in ME/CFS are far from “dead and … |
Ofatumumab-based chemoimmunotherapy effective in CLLHealioAn ofatumumab-based chemoimmunotherapy regimen was well tolerated and similarly effective as a rituximab-based regimen in previously untreated patients with chronic lymphocytic leukemia, accordi…
|
Homegrown Data Mining Uncovers Drug Claims That Are Most Likely to Have …
Atlantic Information Services, Inc. As a result, he and his team — a data analyst and a coder — are focusing on 16 drugs, including Rituximab, Herceptin and Lupron. They set a range of billable units for each drug. Claims for billable units within that range are probably compliant … |
|
A roundup of FDA oncology news from September 2013
Oncology Nurse Advisor … agent is indicated for use in persons who have chronic lymphocytic leukemia (CLL) or who have indolent B-cell non-Hodgkin lymphoma that has progressed during or within 6 months of treatment with rituximab (Rituxan®) or a rituximab-containing regimen. |
Market watch: Upcoming market catalysts in Q4 2013Nature.comSubsequently, data from the second stage of the trial comparing obinutuzumab head-to-head against rituximab, which were both in combination with chlorambucil, demonstrated a significant improv…
Rituximab prevented corticosteroid-requiring chronic GVHDHealioRituximab prophylaxis considerably reduced corticosteroid-requiring chronic graft-vs.-host disease in patients who underwent allogeneic peripheral blood stem cell transplantation, according…
|
NICE backs Roche’s MabThera in rare autoimmune disease
PMLiVE The draft guidance overturns an earlier decision made by NICE which failed to recommend the use of MabThera (rituximab) for NHS use in England and Wales to treat anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis – an inflammation of the … Roche’s MabThera now favoured by NICE in vasculitisPharmaTimes |
Study Findings from Shanghai Jiao-Tong University Provide New Insights into …HispanicBusiness.comThe effect of rituximab alone or combined with the PI3K/AKT/mTOR pathway inhibitor rapamycin was further evaluated in the DLBCL cell lines. A total of 73…